Sirona Biochem Announces Management Changes

Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announces that the Company has terminated Attila Hajdu’s employment by mutual agreement. The Company is pleased to announce the addition of Aleksandra Kasikovic to its team in a new role of Manager, Commercial Development. Aleksandra holds a Master’s of Science degree in Biotechnology from McGill University and an undergraduate degree in Biology and Marketing. Her strong work ethic and capacity for commercially evaluating science will be a valuable asset for Sirona.
Dr. Howard Verrico, CEO of Sirona Biochem, said: “Attila has been instrumental in leading the negotiations towards a global licensing agreement for our skin lightening compound, TFC-1067. We would like to thank Attila for his hard work and want to wish him the very best in his future endeavors.”
“In the fall 2016, a team consisting of members of management, key board members and legal counsel at McMillian LLP was established to oversee licensing negotiations. All members have successfully negotiated definitive licensing agreements in the past and their combined skills cover depth and breadth needed for success. This team is now taking the lead in finalizing a licensing agreement for our superior skin lightening compound, TFC-1067. We anticipate the aforementioned changes will have a positive impact on current partnering activities and anticipated timelines”, he added.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: a third party potential licensees of TFC-1067 may not deliver a term sheet to the company in Q1 2017 or at all; the company may not be able to negotiate a license agreement with a potential licensees of TFC-1067 on terms acceptable to Sirona Biochem; the progress and timing of its clinical trials are uncertain; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing products; unexpected adverse side effects or inadequate therapeutic efficacy of the company’s or licensed products that could delay or prevent product development or commercialization; the scope and validity of patent protection for the company’s or licensed products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.